← All trials
NCT04196530
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2019
- Primary completion
- Jul 1, 2021
- Completion date
- Jan 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Birdie Biopharmaceuticals HK LimitedLead sponsor
- Seven and Eight Biopharmaceuticals IncCollaborator
- Seven and Eight Biopharmaceuticals IncStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.